Teva Recalls Valganciclovir Hydrochloride Oral Solution Due to Foreign Particles
Teva Pharmaceuticals is recalling specific lots of Valganciclovir Hydrochloride for Oral Solution because brown or black particles were found during stability testing.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically involves a situation that might cause temporary or medically reversible adverse health consequences. The hazard is the presence of foreign particles, which is a quality issue but does not involve high-risk pathogens or reported serious injuries.
Plain-English summary
Teva Pharmaceuticals USA, Inc. is recalling 3,623 bottles of Valganciclovir Hydrochloride for Oral Solution, 50 mg/mL, 100 mL. The affected product is identified by NDC 0591-2579-20 and includes lots CBFCN and CBHFG with an expiration date of 05/2020. The recall was initiated because brown or black particles were detected during stability testing.
The product was distributed to wholesalers and distributors throughout the United States. It was manufactured for Actavis Laboratories FL. Inc. and distributed by Actavis Pharma, Inc.
Consumers and healthcare providers should stop using the affected product and contact their pharmacist or healthcare provider for a replacement or refund. Patients should not discontinue their prescribed medication without consulting their healthcare provider.
The recalled product
- Product
- VALGANCICLOVIR HYDROCHLORIDE FOR ORAL (VALGANCICLOVIR HYDROCHLORIDE)
- Brand
- VALGANCICLOVIR HYDROCHLORIDE FOR ORAL
- Manufacturer
- Teva Pharmaceuticals USA, Inc.
- Category
- Drug — Antiviral
- Hazard
- Affected units
- 3,623
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot #: CBFCN
- CBHFG
- Exp 05/2020
Distribution
Distribution scope not specified by the agency.
Related recalls
Same manufacturer · Teva Pharmaceuticals USA, Inc.
See all →- SevereOctreotide Acetate Injectable Suspension Recalled Due to Sterility Assurance
FDA (Drugs) · 2026-05-13
- ModerateClaravis isotretinoin 10 mg capsules recalled for out-of-specification impurity
FDA (Drugs) · 2026-04-29
- ModerateTeva clonidine 0.2 mg patches recalled over unapproved raw material use
FDA (Drugs) · 2026-04-15
- HighTeva isotretinoin 30 mg capsules recalled as superpotent and subpotent
FDA (Drugs) · 2026-04-15
- HighTeva isotretinoin 40 mg capsules recalled as superpotent and subpotent
FDA (Drugs) · 2026-04-15
Same hazard · foreign substance
See all →- ModerateHeritage Pharmaceuticals Recalls Clindamycin Palmitate Hydrochloride Due to Foreign Particles
FDA (Drugs) · 2026-08-19
- HighPrednisolone Acetate Ophthalmic Suspension Recalled for Foreign Substance
FDA (Drugs) · 2026-07-08
- ModerateCorlanor Ivabradine Tablets Recalled for Foreign Substance Contamination
FDA (Drugs) · 2026-07-01
- ModerateCorlanor ivabradine tablets recalled for presence of foreign substance
FDA (Drugs) · 2026-07-01
- LowHydroxyzine Hydrochloride Oral Solution recalled for foreign substance
FDA (Drugs) · 2026-07-01